H.R.6576 - Drug-Price Transparency in Communications Act115th Congress (2017-2018)
|Sponsor:||Rep. Schakowsky, Janice D. [D-IL-9] (Introduced 07/26/2018)|
|Committees:||House - Energy and Commerce|
|Latest Action:||House - 07/27/2018 Referred to the Subcommittee on Health. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.6576 — 115th Congress (2017-2018)All Information (Except Text)
Introduced in House (07/26/2018)
Drug-Price Transparency in Communications Act
This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.
The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.